Welcome to our dedicated page for Nano-X Imaging Ltd. SEC filings (Ticker: NNOX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NANO-X IMAGING LTD (Nanox) SEC filings page for ticker NNOX provides access to the company’s regulatory disclosures as a foreign private issuer listed on NASDAQ. Nanox files an annual report on Form 20-F and furnishes current reports on Form 6-K that cover topics such as capital raises, financial results, shareholder meetings, and significant business developments related to its medical imaging and AI platform.
Recent Form 6-K filings describe a registered direct offering of ordinary shares under an effective shelf registration statement on Form F-3, including the related placement agency agreement, purchase agreement, and legal opinions. Other 6-K reports furnish press releases announcing quarterly financial results, non-GAAP financial measures reconciled to GAAP, and notices and proxy materials for the company’s annual general meeting of shareholders. These documents allow investors to review how Nanox funds its operations and how it reports performance across its Nanox.ARC, radiology services, and AI solutions divisions.
Through this page, users can also track filings that reference Nanox’s imaging systems and AI solutions, including disclosures about commercialization activities, acquisitions such as VasoHealthcare IT, and integration of AI software with health IT infrastructure. The exhibits to these filings may include agreements, opinions, and other materials that provide additional context on Nanox’s operations and capital structure.
Stock Titan enhances access to these filings with AI-powered summaries that explain the key points of lengthy documents, helping readers quickly understand items such as registered offerings, financial updates, or meeting notices. Real-time updates from EDGAR ensure that new 6-Ks, 20-Fs, and related registration statements appear promptly, while dedicated sections highlight ownership and insider-related filings when available. This combination of original SEC documents and AI-generated insights helps investors and researchers analyze NNOX regulatory information more efficiently.
Nano-X Imaging reported fourth-quarter 2025 revenue of $3.7 million, up from $3.0 million a year earlier, mainly from teleradiology and AI/software services. The company posted a GAAP net loss of $33.4 million versus $14.1 million, driven largely by a $17.5 million non-cash impairment tied to restructuring its Korean chip manufacturing line.
For full-year 2025, revenue reached $13.0 million with a net loss of $75.0 million. Nano-X is shifting to a more outsourced manufacturing model and expects about $18.0 million in total restructuring charges. Commercially, it has about 36 Nanox.ARC systems in deployment stages, expects roughly 17 additional systems to be installed in the coming months, and has U.S. distribution agreements for about 360 Capex systems over the next two to three years, though many systems are not yet generating revenue.
The company is targeting $35 million in 2026 revenue, but notes growth will depend on system activations and partner performance. Liquidity remains a key focus: as of December 31, 2025, cash, deposits and marketable securities totaled $60.0 million, after $40.8 million negative operating cash flow and $21.4 million positive financing cash flow in 2025. Nano-X also announced a planned CFO transition from Ran Daniel to Guy Nathanzon in mid-2026.
Nano-X Imaging Ltd. executive Yahav Attias Gali filed an initial ownership report as Chief Corporate Resources officer. The filing lists direct holdings of ordinary shares and stock options, including options over 6,500, 12,500 and 40,000 ordinary shares with exercise prices between $11.52 and $23.86 and expirations from 2031 to 2033. A footnote explains that certain ordinary shares represent restricted share units granted on February 5, 2026, vesting in two equal installments over 12 and 24 months.
Nano-X Imaging Ltd. executive Saban Sharon, General Manager of the AI Division, reported his initial beneficial ownership in the company. He holds 26,316 ordinary shares directly, including shares underlying restricted share units granted on February 5, 2026 that vest 50% after 12 months and 50% after 24 months from the grant date. He also holds a stock option covering 15,000 ordinary shares at an exercise price of $17.63 per share, granted on September 15, 2022. These options vest in 16 equal quarterly installments of 6.25% each and are scheduled to be fully exercisable by September 15, 2026, with an expiration date of September 15, 2032.
Nano-X Imaging Ltd. director Erez Alroy filed an initial ownership report showing direct holdings of the company’s ordinary shares and stock options. He reports 6,962 ordinary shares in one line and 17,544 ordinary shares in another, reflecting different grant types.
Alroy also holds stock options covering 50,000 ordinary shares with a fixed exercise price of $17.63 per share that expire on December 28, 2032, and options over 10,000 ordinary shares at $11.52 per share expiring on December 31, 2033. Footnotes explain that one ordinary-share position consists of restricted share units granted on December 10, 2025, vesting in twelve equal monthly installments over one year, and that the option grants vest in 16 equal quarterly installments over four years from their respective reference dates.
Nano-X Imaging Ltd files Amendment No. 1 to its Form F-3 registration statement to furnish the form of indenture as Exhibit 4.7 and an updated consent of its independent auditors. The prospectus in Part I is unchanged. The registration contemplates sales "from time to time after the effective date".
The filing also restates corporate governance provisions under Israeli law: the company’s articles permit exculpation, indemnification and officers’ insurance to the fullest extent allowed, and indemnification caps include $50 million, 25% of shareholders’ equity, or aggregate offering proceeds, as described. The amendment is signed by the CEO and authorized U.S. agent on March 26, 2026.
Nano-X Imaging Ltd. CFO Daniel Ran reported a disposition of ordinary shares back to the company. On March 18, 2026, he transferred 39,474 ordinary shares to the issuer at a stated price of $0.00 per share. After this issuer-related disposition, he directly holds 46,424 ordinary shares, according to the filing.
Nano-X Imaging Ltd. director Ronen Nehama filed an initial ownership report showing his equity position in the company. The filing lists a stock option to buy 50,000 ordinary shares at an exercise price of $17.63 per share, expiring on December 31, 2033, alongside direct holdings of ordinary shares, including shares underlying restricted share units that vest in twelve equal monthly installments from a December 10, 2025 grant.
Nano-X Imaging Ltd. director Kainan Noga filed an initial ownership report showing a mix of ordinary shares, restricted share units and stock options in the company. One block of ordinary shares consists of restricted share units granted on December 10, 2025 that vest in twelve equal monthly installments over one year.
Noga also holds stock options over 12,505, 50,000 and 10,000 ordinary shares with exercise prices of $64.6100, $17.6300 and $11.5200, expiring in 2031, 2032 and 2033, respectively. Some ordinary shares are held indirectly through I.B.L. Business Consulting Ltd., which is wholly owned by Noga.
Nano-X Imaging Ltd. disclosed the initial holdings of Chief Executive Officer Erez Meltzer. He directly holds 60,584 ordinary shares. He also holds stock options over 40,234 ordinary shares at an exercise price of $2.2100 per share expiring on February 11, 2030, and options over 300,000 ordinary shares at $23.8400 per share expiring on January 2, 2032, both fully vested and exercisable. Additional options over 150,000 ordinary shares at $11.5200 per share expire on April 16, 2034 and vest over four years, with 25% vested after one year and 6.25% vesting quarterly until April 16, 2028.
Nano-X Imaging Ltd. executive Dara James, GM of the Source & Services Division, filed an initial ownership report showing equity-based compensation. James holds stock options over 100,000 ordinary shares at an exercise price of $49.68 expiring on January 18, 2031, plus options over 25,000 and 10,000 shares at $17.63 expiring in 2032, and 55,000 shares at $11.52 expiring in 2033. The filing also reports 39,474 ordinary shares consisting of restricted share units granted on February 5, 2026, with half vesting after 12 months and the rest after 24 months.